- sr0213
Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia
Updated: Mar 8
Promethean BioPharma supports the work of Mind Medicine Australia and encourages their submissions to the Therapeutic Goods Administration in relation to the rescheduling of psilocybin and MDMA from Schedule 9 to Schedule 8.
For more information:
https://mindmedicineaustralia.org.au/